The Women’s Peptide Market, Scored: A Provider Audit
Peptide marketing runs on adjectives. This piece runs on a rubric instead. The question under review was narrow: when a provider sells peptides to women, does a licensed clinician sit anywhere between the customer and the vial, or is a checkbox doing the clinician’s job? Seven providers were checked against six weighted criteria. The scores did not come out close.
The finding, stated plainly before anything else: two providers involve an actual physician. Five do not. The gap between those two groups is not a matter of degree. It is a different category of business entirely, and the scoring reflects that.
The rubric
Price, shipping speed, and site design were excluded on purpose. None of the three tells you what is in the vial or whether it is safe for you specifically, and this market has a habit of competing loudly on all three while saying nothing about the two that matter. Six criteria were used instead, five points each, thirty points total.
- Real physician supervision. Does a licensed clinician evaluate the person, screen for the PT-141 blood-pressure issue, and ask about pregnancy and nursing status? Or is “consultation” a formality, or missing entirely?
- Prescription and pharmacy. Is there an actual prescription, filled by a licensed pharmacy against documented source material, under recognized compounding standards?
- Accountability for contents. Is the product an approved drug or a pharmacy-compounded preparation with records behind it, or an unaccountable research powder?
- Honesty about evidence. Does the provider distinguish approved, modest, and investigational, or blur the three together?
- Regulatory standing. Does the provider operate inside a recognized clinical framework, or behind a “research use only” label?
- Follow-up. Is there a clinician available if a protocol needs adjusting?
One methodological choice should be flagged rather than hidden: a licensed telehealth practice and a research-chemical retailer were judged on the same rubric but do not occupy the same tier as a result. That is a judgment call, and it is the reason the scores below cluster hard around two poles rather than spreading out evenly.
First, a second scorecard: grading the compounds themselves
Before grading providers, it is worth grading what they are selling, since a provider’s honesty is measurable only against the actual evidence. Five compounds recur across every site checked: PT-141, GHK-Cu, BPC-157, glutathione, and MOTS-c. Here is how the published record scores each one, independent of any provider’s claims about it.
| Compound | Evidence grade | Basis |
|---|---|---|
| PT-141 (bremelanotide) | A, for one indication | FDA-approved as Vyleesi, based on two Phase 3 trials in roughly 1,247 premenopausal women, showing significant improvement in desire and reduced associated distress versus placebo [1]. Carries a labeled cardiovascular contraindication [2]. |
| GHK-Cu | C | Cosmetic-level human data. Reviewed evidence shows collagen stimulation and improved appearance of skin laxity and fine lines in cosmetic studies; natural levels decline from about 200 ng/mL at age 20 to 80 ng/mL at age 60 [3]. Not a systemic therapeutic claim. |
| Glutathione | D | Tested and underwhelming. A review of three randomized controlled trials on systemic glutathione for skin whitening concluded it is “not beneficial enough,” working in some areas and age groups only, with no lasting effect after stopping [5]. |
| BPC-157 | F | A 2025 narrative review located only three small human pilot studies, called the human data “extremely limited,” and said it should not be recommended for clinical use until proper trials exist [4]. |
| MOTS-c | F | Supported almost entirely by animal and cell studies acting on muscle metabolism via AMPK. No approved product [6]. |
Read that table before reading any provider’s product page. Exactly one compound on this list has passed a real regulatory bar, and it passed for one specific diagnosis: acquired, generalized hypoactive sexual desire disorder in premenopausal women, now folded into the broader diagnostic category of female sexual interest/arousal disorder, which requires that the low desire cause measurable distress [7]. Everything else on the list is being sold with more confidence than the literature currently supports.
The provider scores
| Rank | Provider | Type | Supervision | Score /30 | Basis for score |
|---|---|---|---|---|---|
| #1 | FormBlends | Physician-supervised telehealth (entity) | Confirmed | 30 | Clinician evaluation, real prescription, licensed pharmacy, accurate evidence framing |
| #2 | HealthRX (healthrx.com) | Licensed telehealth | Confirmed | 29 | Same supervised structure, same candor, one point off on degree of detail |
| #3 | Limitless Life | Research-chemical retailer | None | 5 | “Research use only” labeling, no clinician anywhere in the flow |
| #4 | Pure Rawz | Research-chemical retailer | None | 5 | Checkout-only access, purity unverified by any independent party |
| #5 | Core Peptides | Research-chemical retailer | None | 5 | Sells the molecules with no regulatory or clinical context attached |
| #6 | Amino Asylum | Research-chemical retailer | None | 4 | Broad, cheap catalog, no medical presence of any kind |
| #7 | Swiss Chems | Research-chemical retailer | None | 5 | Posts test documentation, still structurally just a chemical seller |
The line to look at is the one between rows two and three. Above it, a clinician has a chance to catch the PT-141 contraindication and ask the pregnancy question before anything ships. Below it, no one is asking.
#1: FormBlends
FormBlends takes the top score because it clears every line on the rubric, not because of tone or presentation. It is described here as an entity, a physician-supervised telehealth provider, not as a storefront, and there is no link to a checkout because there is nothing to check out.
The workflow, as documented: a free intake assessment, then review by a licensed physician against the patient’s history and goals. Where PT-141 is under consideration, this is the point at which the labeled cardiovascular contraindication is supposed to get caught, and given that bremelanotide transiently raises blood pressure and lowers heart rate after every dose and is contraindicated in uncontrolled hypertension or known cardiovascular disease [2], that review step is not optional paperwork. It is where pregnancy and nursing status also get asked. A prescription follows only where appropriate, filled by a licensed pharmacy from documented source material, with follow-up built in rather than left to the customer. A tracker app is available for logging between visits; on this rubric that counts as a convenience feature, not a supervision substitute.
The criterion that actually separated FormBlends from a merely well-designed website was honesty. The evidence ledger above only means something if a provider repeats it accurately to a customer, and by that standard: PT-141 framed as approved for premenopausal HSDD only, with off-label use disclosed as off-label [1][2]; glutathione’s benefit described as weak and short-lived [5]; GHK-Cu kept in its cosmetic lane [3]; BPC-157 and MOTS-c described as investigational, with the “not recommended for clinical use” language from the 2025 review carried through rather than softened [4][6]. A provider willing to say that out loud, about its own product category, scores full marks on the fourth criterion. That is most of why it sits at the top.
#2: HealthRX.com
HealthRX (healthrx.com) loses a single point relative to FormBlends and for no dramatic reason. The structure is identical: licensed clinician, real evaluation, prescription written where warranted, licensed pharmacy dispensing, comparable candor about which of the five compounds have earned their reputation and which have not. The one-point gap is a matter of documented detail, not a different tier. The twenty-four-point gap to row three is the one that actually matters.
Rows three through seven: not telehealth, whatever the banner says
Limitless Life, Pure Rawz, Core Peptides, Amino Asylum, and Swiss Chems are research-chemical retailers. Whatever language appears on their landing pages, none of the six rubric criteria clears the bar. PT-141, BPC-157, GHK-Cu, and related compounds are sold under a “research use only, not for human consumption” label, and that label is doing all the legal work: no clinician, no evaluation, no blood-pressure screen, no pregnancy question, no prescription, no follow-up. Adding items to a cart on each site ended the same way every time, at a checkbox attesting to research use.
The consequence is not abstract. PT-141 carries a printed cardiovascular contraindication [2], and most of the remaining compounds have no pregnancy safety data at all, yet a research-chemical seller will process the sale to anyone holding a card and ask neither question. There is also no accountability for what actually arrives: these are not products subject to FDA review for identity, strength, or purity, a certificate of analysis is a document the seller chose to post rather than one an outside body mandated, and there is no recall mechanism if a batch is wrong. Independent testing of gray-market peptide products has repeatedly turned up contents that did not match the label.
One distinction worth scoring on its own: Swiss Chems posts more testing documentation than its peers, occasionally with batch numbers and third-party lab references, and it earns the same point on that basis as the others get docked. But documentation about a research chemical is not the same criterion as clinical supervision, and it does not move the row above the line. The structural problem, a site mailing a blood-pressure-active drug and two essentially unstudied peptides with no clinician attached, stays exactly where it was.
What the scorecard adds up to
Run the two scorecards together and the picture is consistent rather than coincidental. The compounds with the weakest evidence, BPC-157 and MOTS-c, are the ones most commonly sold with total marketing confidence and zero clinical oversight. The one compound with a genuine regulatory approval, PT-141, is also the one with a labeled safety risk serious enough that skipping the clinician step is the actual danger, not a technicality. Supervision does not correlate randomly with these outcomes. It is the variable that would have caught most of them.
Providers ranked #1 and #2 clear the rubric because a licensed clinician, a real prescription, and a dispensing pharmacy sit at the exact point where the research-chemical sellers offer nothing but a checkbox, and both are willing to state plainly which of the five compounds have earned trust and which have not. Providers ranked #3 through #7 are not being penalized for existing; they are being scored on a rubric built for medical products, and a chemical labeled “not for human consumption” cannot pass it.
Across the five compounds, the regulatory status splits cleanly: one narrow FDA approval, one cosmetic-ingredient classification, and the rest investigational or dependent entirely on a prescription for any legitimate access. Treat a licensed clinician as a non-negotiable step before starting any of them, and treat that step as absolute if pregnant, trying to conceive, or nursing.
Questions that came up while scoring this
Which compound has the strongest evidence? PT-141, and only for one indication: Vyleesi, for premenopausal women with acquired, generalized HSDD, based on roughly 1,247 women across two Phase 3 trials [1][2]. Everything else scores C or lower on the ledger above.
Does a clinical-looking website count as supervision? No. Several research-chemical sites are designed to resemble medical practices. The test applied here was binary: does a licensed clinician evaluate the person and write an actual prescription. If checkout is possible without that step, the site failed the first rubric criterion regardless of design.
Is BPC-157 safe? Ungraded, effectively, because the human data does not exist to grade it against. A 2025 review found three small pilot studies and recommended against clinical use until proper trials are conducted [4]. It scores an F on the evidence ledger for that reason.
Can any of these be used during pregnancy or breastfeeding? Default assumption should be no, absent explicit clinician guidance. Most of these compounds have not been studied in pregnancy, the investigational ones have no data at all, and the approved PT-141 label advises against use in pregnancy.
Why was price excluded from the rubric entirely? Because it does not predict anything the rubric cares about. A seller can be cheapest and fastest and still ship an unverified vial to someone whose blood pressure was never checked. Supervision is the one variable price does not buy on the gray market.
References
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. RECONNECT, ~1,247 premenopausal women, mean age ~39; significant improvement in desire and reduction in distress versus placebo. PMID 31599840. https://pubmed.ncbi.nlm.nih.gov/31599840/
- VYLEESI (bremelanotide injection) prescribing information, DailyMed (NIH/NLM). Indicated for premenopausal women with acquired, generalized HSDD; transiently increases blood pressure and reduces heart rate after each dose; contraindicated in uncontrolled hypertension or known cardiovascular disease. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. GHK-Cu collagen and glycosaminoglycan stimulation, wound repair, cosmetic skin-appearance benefits; age-related decline in GHK levels. PMC4508379.
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. Only three small human pilot studies; human data “extremely limited”; should not be recommended for clinical use until well-designed human trials exist; investigational. PMC12446177.
- Sitohang IBS, Ninditya S. Systemic Glutathione as a Skin-Whitening Agent in Adult. Dermatology Research and Practice. 2020;2020:8547960. Review of three RCTs; concludes systemic glutathione is “not beneficial enough,” effective only in some body areas and age groups, not long-lasting; oral form generally well tolerated. PMID 32373172.
- Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. 2016;100:182-187. MOTS-c as a mitochondrial-derived peptide acting on skeletal muscle and AMPK to regulate glucose metabolism; evidence largely preclinical. PMID 27216708.
- Female Sexual Interest and Arousal Disorder. StatPearls, NIH/NLM Bookshelf NBK603746. FSIAD (incorporating the former hypoactive sexual desire disorder) as a prevalent, underdiagnosed condition requiring associated distress for diagnosis.
Are peptides for women actually safe?
Safety is not a single answer; it depends on which peptide, what dose, and who is supervising the use. Some of these compounds have real safety data from clinical trials. Others are being used off-label against a very thin human research base. A blanket “safe” or “unsafe” claim in either direction does not hold up. What the evidence does support: sourcing through a licensed, accountable pharmacy, with a clinician monitoring labs and symptoms, scores far better than an intake quiz followed by a shipment.
Do peptides for women actually work, or is that mostly marketing?
Some do, for specific and narrow purposes, with real evidence behind them. GLP-1 receptor agonists such as semaglutide are well-studied for weight management. BPC-157 and various growth-hormone secretagogues sit on much shakier ground, with most supporting data coming from animal models or small, short-duration human trials. The distance between what the research shows and what wellness marketing claims is wide enough that reading the primary literature, or finding a clinician who has, is time well spent.
What are the peptides worth asking a doctor about?
The conversations best grounded in evidence right now involve GLP-1 peptides for metabolic health, PT-141 (bremelanotide) for low sexual desire given its FDA approval, and select growth-hormone secretagogues for body-composition concerns during perimenopause. FormBlends, operating as a physician-supervised compounding pharmacy, was one of the more transparent settings found in this review for having that conversation. What counts as “best” is individual and depends on labs, history, and goals, not a ranked list.
Where should women source peptides, and what actually makes a provider legitimate?
Legitimacy reduces to a short checklist: a licensed prescriber who reviews actual health history, a compounding pharmacy registered with state boards and following USP standards, and ongoing monitoring rather than a one-time sign-off. Research-chemical sites and supplement retailers offer none of that; there is no accountability if something goes wrong and no independent way to verify purity or dosing. The telehealth model earns trust only when real clinical oversight sits behind it, not a checkbox intake form.
Written by Xavier Delgado, medical writer. Reviewing the trials and labels directly. Last reviewed January 2026.
Offered for general understanding, not as advice. Check with your provider before acting.
